|
|
|
| Efficacy of Bevacizumab Combined with Paclitaxel and its Effect on Patients' Immune Function in the Treatment of Advanced Breast Cancer |
| TAN Yue, LI Gang, LI Xue-lian, et al |
| Department of Oncology,Minhang Branch,Fudan University Affiliated Cancer Hospital,Shanghai 200240 |
|
|
|
|
Abstract 【Objective】To investigate the efficacy of bevacizumab combined with paclitaxel in the treatment of advanced breast cancer and its effect on patients' immune function. 【Methods】Eighty patients with advanced breast cancer admitted to our hospital were randomly divided into two groups,with 40 patients in each group. The observation group was treated with paclitaxel + bevacizumab,while the control group was treated with paclitaxel alone. The clinical efficacy,serum-related markers [Vascular Endothelial Growth Factor (VEGF),Basic Fibroblast Growth Factor (bF-GF)],tumor markers [Serum Carcinoembryonic Antigen (CEA),Carbohydrate Antigen 125 (CA125)],and immune function indicators (CD3+,CD4+,CD4+/CD8+) level changes and the incidence of adverse reactions in both groups were compared. 【Results】The total remission rate of the observation group was 75.00% (30/40),which was significantly higher than 50.00% (20/40) of the control group. And the difference was statistically significant (P<0.05). After treatment,the levels of VEGF,bF-GF,CEA,and CA125 in both groups decreased compared to before treatment (P<0.05),and the aforementioned indicators in the observation group were lower than those in the control group (P<0.05). After treatment,the levels of CD3+,CD4+,and CD4+/CD8+ in both groups increased compared to before treatment (P<0.05),and the levels of CD3+,CD4+,and CD4+/CD8+ in the observation group were higher than those in the control group (P<0.05). The incidence of adverse reactions in both groups showed no statistical difference (P>0.05). 【Conclusion】The use of bevacizumab combined with paclitaxel chemotherapy in advanced breast cancer can improve the immune function of patients,effectively reduce tumor markers and serum-related factors,and demonstrate good clinical efficacy. The combination treatment does not increase adverse reactions,which is worthy of clinical promotion and application.
|
|
Received: 16 May 2023
|
|
|
|
|
|
[1] 张璐璐,刘芸,段文冰,等. 乳腺癌患者部分外周血指标的变化及肿瘤标志物的诊断价值[J].中国医药,2018,13(3):421-425.
[2] 曹慧,王冰,李芳颖,等. 血清氨基酸对晚期乳腺癌白蛋白结合型紫杉醇化疗疗效预测价值分析[J].中华肿瘤防治杂志,2020,27(11):896-902.
[3] 朱海峰. 黄芪注射液联合紫杉醇质脂体对中晚期乳腺癌患者TFF1、免疫功能的影响[J].现代中西医结合杂志,2021,30(18):2007-2009.
[4] 张柔媚,马春来,钟明康. 贝伐珠单抗联合紫杉醇治疗转移性乳腺癌临床疗效及预后分析[J].中国肿瘤临床与康复,2022,29(12):1409-1412.
[5] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2011版)[J].中国癌症杂志,2011,21(5):54-104.
[6] 薛卫成,阚秀. 介绍乳腺癌TNM分期系统(第6版)[J].诊断病理学杂志,2008,15(3):161-164.
[7] 杨学宁,吴一龙. 实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90.
[8] 孟令新,曾琴琴,孟芹,等. 安罗替尼与贝伐珠单抗分别联合紫杉醇加卡铂治疗晚期肺腺癌的临床效果[J].中国医药,2019,14(8):1164-1168.
[9] 梁平,王玉栋,白靖,等. 贝伐珠单抗联合紫杉醇用于HER-2阴性转移性乳腺癌一线治疗的药物经济学评价[J].中国现代应用药学,2021,38(1):82-86.
[10] YAMAMOTO Y,YAMASHIRO H,TOH U,et al. Prospective observational study of bevacizumab combined with paclitaxel as first-or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study[J].Breast Cancer,2021,28(1):145-160.
[11] 杜林娟,刘霜,李明,等. 贝伐珠单抗联合化疗治疗晚期乳腺癌疗效及安全性的Meta分析[J].肿瘤,2021,41(3):197-205.
[12] HARTER P,MOURET-REYNIER M A,PIGNATA S,et al. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed,advanced ovarian cancer in the phase Ⅲ PAOLA-1/ENGOT-ov25 trial[J].Gynecol Oncol,2022,164(2):254-264.
[13] 张翠花. 阿帕替尼联合注射用紫杉醇治疗晚期乳腺癌临床疗效及对中期因子血小板因子4表达的影响[J].山西医药杂志,2020,49(19):2641-2643. |
|
|
|
2023, Vol. 40 
